Brief: Essex Bio-Technology Gets Approval For Multi-Dose Diquafosol Sodium Eye Drops In PRC
July 23 (Reuters) - Essex Bio-Technology Ltd 1061.HK: APPROVAL TO COMMERCIALISE MULTI-DOSE DIQUAFOSOL SODIUM EYE DROPS IN PRC APPROVAL FOR UNIT FOR MULTI-DOSE DIQUAFOSOL SODIUM EYE DROPS FROM NMPA Further company coverage: 1061.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Essex Bio-Technology
See all newsHong Kong's Essex Bio-Technology H1 revenue falls
Brief: Essex Bio-Technology Posts HY Profit Of HK$110.7 MLN
Brief: Essex Bio-Technology Expects 10% Revenue And 30% Profit Decrease For HY
Brief: Shanghai Henlius Biotech Says Phase 3 Study Of HLX04-O For WAMD Meets Primary Endpoint
Brief: Essex Bio-Technology Posts Final Dividend Of HK$0.07 Per Share